Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ondine BiomedicalFRA:VF5 38 3-Year RORE % is -8.21 as of Dec. 2025. GuruFocus rates FRA:VF5 with a GF Score™ of 38/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 1,291 Biotechnology companies, Ondine Biomedical ranks better than 52.9% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Ondine Biomedical's 3-Year RORE % for the quarter that ended in Dec. 2025 was -8.21%.
The industry rank for Ondine Biomedical's 3-Year RORE % or its related term are showing as below:
FRA:VF5's 3-Year RORE % is ranked better than 52.9% of 1291
companies
in the Biotechnology industry
Industry Median: -11.44
vs FRA:VF5: -8.21
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Ondine Biomedical 3-Year RORE % Related Terms
Ondine Biomedical 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Ondine Biomedical's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VF5 vs VRTX, REGN, ALNY: 3-Year RORE % Comparison
For the Biotechnology subindustry, Ondine Biomedical's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ondine Biomedical 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ondine Biomedical's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Ondine Biomedical's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Ondine Biomedical (FRA:VF5) has a 3-Year RORE % of -8.21 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Ondine Biomedical and its competitors. According to the industry distribution chart, Ondine Biomedical ranks #608 out of 1291 companies in the Biotechnology industry, placing it in the top 47.1%.
Is Ondine Biomedical's 3-Year RORE % too high?
Ondine Biomedical's current 3-Year RORE % is -8.21. Based on the distribution chart, Ondine Biomedical ranks #608 out of 1291 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ondine Biomedical has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ondine Biomedical's 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ondine Biomedical ranks #608 out of 1291 companies for 3-Year RORE %. This puts Ondine Biomedical in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Ondine Biomedical and its competitors. Ondine Biomedical's current 3-Year RORE % is -8.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ondine Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Ondine Biomedical (FRA:VF5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.15 — trading 66.7% above its estimated fair value. The current 3-Year RORE % is -8.21. Ondine Biomedical's overall GF Score™ is 38/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Ondine Biomedical (FRA:VF5), the current 3-Year RORE % is -8.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ondine Biomedical (FRA:VF5) Overvalued in 2026?
Based on GuruFocus' analysis, Ondine Biomedical stock appears to be overvalued.
The current stock price of €0.15 is trading 66.7% above its estimated GF Value™ of €0.09.
GuruFocus considers Ondine Biomedical to be Significantly Overvalued.
Key valuation signals for FRA:VF5:
3-Year RORE %: -8.21
GF Value™: €0.09 vs. price of €0.15 (66.7% above fair value)
No single metric tells the full story. See the FRA:VF5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
38GF Score
Get the complete analysis for FRA:VF5
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VF5 has been successfully added to your 
